Display options
Cite
Moriconi C, Civita P, Neto C, et al. Caveolin-1, a Key Mediator Across Multiple Pathways in Glioblastoma and an Independent Negative Biomarker of Patient Survival. Front Oncol. 2021;11:701933doi: 10.3389/fonc.2021.701933.
Moriconi, C., Civita, P., Neto, C., Pilkington, G. J., & Gumbleton, M. (2021). Caveolin-1, a Key Mediator Across Multiple Pathways in Glioblastoma and an Independent Negative Biomarker of Patient Survival. Frontiers in oncology, 11701933. https://doi.org/10.3389/fonc.2021.701933
Moriconi, Chiara, et al. "Caveolin-1, a Key Mediator Across Multiple Pathways in Glioblastoma and an Independent Negative Biomarker of Patient Survival." Frontiers in oncology vol. 11 (2021): 701933. doi: https://doi.org/10.3389/fonc.2021.701933
Moriconi C, Civita P, Neto C, Pilkington GJ, Gumbleton M. Caveolin-1, a Key Mediator Across Multiple Pathways in Glioblastoma and an Independent Negative Biomarker of Patient Survival. Front Oncol. 2021 Aug 20;11:701933. doi: 10.3389/fonc.2021.701933. eCollection 2021. PMID: 34490102; PMCID: PMC8417742.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2021 Aug 20;11:701933. doi: 10.3389/fonc.2021.701933. eCollection 2021.

Caveolin-1, a Key Mediator Across Multiple Pathways in Glioblastoma and an Independent Negative Biomarker of Patient Survival.

Frontiers in oncology

Chiara Moriconi, Prospero Civita, Catia Neto, Geoffrey J Pilkington, Mark Gumbleton

Affiliations

  1. School of Pharmacy and Pharmaceutical Sciences, College of Biomedical and Life Sciences, Cardiff University, Cardiff, United Kingdom.
  2. Department of Pathology and Cell Biology, Columbia University, New York Presbyterian Hospital, New York, NY, United States.
  3. Brain Tumour Research Centre, School of Pharmacy & Biomedical Sciences, University of Portsmouth, Portsmouth, United Kingdom.
  4. Department of Basic and Clinical Neuroscience, Division of Neuroscience, Institute of Psychiatry & Neurology, King's College London, London, United Kingdom.

PMID: 34490102 PMCID: PMC8417742 DOI: 10.3389/fonc.2021.701933

Abstract

Glioblastoma (GB) remains an aggressive malignancy with an extremely poor prognosis. Discovering new candidate drug targets for GB remains an unmet medical need. Caveolin-1 (Cav-1) has been shown to act variously as both a tumour suppressor and tumour promoter in many cancers. The implications of Cav-1 expression in GB remains poorly understood. Using clinical and genomic databases we examined the relationship between tumour Cav-1 gene expression (including its spatial distribution) and clinical pathological parameters of the GB tumour and survival probability in a TCGA cohort (n=155) and CGGA cohort (n=220) of GB patients. High expression of Cav-1 represented a significant independent predictor of shortened survival (HR = 2.985, 5.1

Copyright © 2021 Moriconi, Civita, Neto, Pilkington and Gumbleton.

Keywords: CGGA; TCGA; caveolin-1; gender; glioblastoma; invasion; prognostic; survival

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Cancer Lett. 2006 Feb 20;233(1):10-5 - PubMed
  2. Sci Rep. 2018 Jan 8;8(1):7 - PubMed
  3. Science. 2014 Jun 20;344(6190):1396-401 - PubMed
  4. Cancer Sci. 2012 Feb;103(2):269-73 - PubMed
  5. N Engl J Med. 2005 Mar 10;352(10):987-96 - PubMed
  6. BJU Int. 2004 Feb;93(3):291-6 - PubMed
  7. Cancer Metastasis Rev. 2007 Jun;26(2):225-39 - PubMed
  8. Ann Med. 2004;36(8):584-95 - PubMed
  9. Am J Surg Pathol. 2007 May;31(5):760-9 - PubMed
  10. Proteomics. 2015 Aug;15(15):2597-601 - PubMed
  11. Neuro Oncol. 2018 Nov 9;20(suppl_7):vii17-vii26 - PubMed
  12. Mol Cell Biol. 2014 Aug;34(16):3013-23 - PubMed
  13. BMC Med Genomics. 2019 Mar 20;11(Suppl 7):34 - PubMed
  14. Cancer Cell. 2010 Jan 19;17(1):98-110 - PubMed
  15. Semin Cancer Biol. 2015 Dec;35:71-84 - PubMed
  16. Brain. 2019 Apr 1;142(4):847-866 - PubMed
  17. Science. 2018 May 11;360(6389):660-663 - PubMed
  18. Cell Cycle. 2013 May 15;12(10):1510-20 - PubMed
  19. J Pathol. 2008 Dec;216(4):387-93 - PubMed
  20. Oncogene. 2004 Sep 9;23(41):6967-79 - PubMed
  21. Cell Adh Migr. 2012 Nov-Dec;6(6):509-12 - PubMed
  22. Nat Commun. 2016 Apr 20;7:11371 - PubMed
  23. Hum Pathol. 2009 Dec;40(12):1738-46 - PubMed
  24. Med Oncol. 2012 Jun;29(2):977-84 - PubMed
  25. Oncol Lett. 2019 Mar;17(3):2867-2873 - PubMed
  26. Neuro Oncol. 2017 Nov 6;19(suppl_5):v1-v88 - PubMed
  27. Oncol Lett. 2016 Mar;11(3):1615-1620 - PubMed
  28. Genomics Proteomics Bioinformatics. 2021 Mar 2;: - PubMed
  29. J Neuropathol Exp Neurol. 2009 Apr;68(4):425-31 - PubMed
  30. Cancer Res. 2011 Feb 1;71(3):832-41 - PubMed
  31. J Cell Mol Med. 2013 Mar;17(3):325-36 - PubMed
  32. Biotechnol J. 2017 Oct;12(10): - PubMed
  33. Sci Transl Med. 2019 Jan 2;11(473): - PubMed
  34. Clin Neurol Neurosurg. 2015 Dec;139:138-43 - PubMed
  35. Cancer Metastasis Rev. 2020 Jun;39(2):471-483 - PubMed
  36. Nat Methods. 2012 Jun 28;9(7):676-82 - PubMed
  37. Transl Oncol. 2014 Apr;7(2):196-205.e1 - PubMed
  38. Pathol Res Pract. 2014 Aug;210(8):514-20 - PubMed
  39. Sci Rep. 2018 Feb 5;8(1):2338 - PubMed
  40. Nat Rev Cancer. 2003 Jul;3(7):489-501 - PubMed
  41. Pathol Oncol Res. 2009 Sep;15(3):495-502 - PubMed
  42. Am J Pathol. 1994 Aug;145(2):301-9 - PubMed
  43. J Vis Exp. 2015 May 01;(99):e52686 - PubMed
  44. Mol Biol Cell. 2013 Jul;24(13):2134-45 - PubMed
  45. Curr Mol Med. 2018;18(4):199-206 - PubMed
  46. FEBS J. 2013 May;280(10):2399-417 - PubMed
  47. J Transl Med. 2013 Oct 11;11:255 - PubMed
  48. Cell. 2013 Oct 10;155(2):462-77 - PubMed
  49. Cancer Manag Res. 2010 May 10;2:111-22 - PubMed
  50. Acta Neurochir (Wien). 2003 Sep;145(9):825-38 - PubMed
  51. Neuro Oncol. 2014 Sep;16(9):1263-73 - PubMed
  52. Cancer Metastasis Rev. 2008 Dec;27(4):715-35 - PubMed
  53. Neuro Oncol. 2017 Nov 29;19(12):1599-1606 - PubMed
  54. Neuro Oncol. 2017 Mar 1;19(3):383-393 - PubMed
  55. Front Oncol. 2020 Feb 21;10:183 - PubMed
  56. Br J Cancer. 2008 Jul 22;99(2):327-34 - PubMed
  57. Int J Cancer. 2012 Oct 15;131(8):1779-89 - PubMed
  58. CNS Neurosci Ther. 2019 Mar;25(3):343-354 - PubMed
  59. Cancer Metastasis Rev. 2020 Jun;39(2):435-453 - PubMed
  60. Acta Neuropathol. 2015 Oct;130(4):587-97 - PubMed
  61. Cells Tissues Organs. 2007;185(1-3):7-19 - PubMed
  62. Cell. 1998 Sep 4;94(5):625-34 - PubMed
  63. PLoS One. 2014 Oct 31;9(10):e110316 - PubMed
  64. J Cell Biochem. 2018 Feb;119(2):1285-1290 - PubMed
  65. Neuro Oncol. 2013 Apr;15(4):469-79 - PubMed
  66. Stem Cell Res Ther. 2013 Jul 30;4(4):90 - PubMed
  67. Oncol Rep. 2011 Feb;25(2):359-66 - PubMed
  68. Nat Rev Cancer. 2015 Apr;15(4):225-37 - PubMed
  69. Cancer Res. 2015 Nov 1;75(21):4466-73 - PubMed
  70. Cells. 2017 Nov 22;6(4): - PubMed
  71. J Biol Chem. 2008 May 16;283(20):13714-24 - PubMed
  72. Nat Commun. 2015 Aug 26;6:8093 - PubMed
  73. Cancer Treat Rev. 2019 Nov;80:101896 - PubMed
  74. Cancers (Basel). 2014 Jan 27;6(1):226-39 - PubMed
  75. Annu Rev Cell Dev Biol. 2018 Oct 6;34:111-136 - PubMed
  76. J Neurooncol. 2019 Jun;143(2):207-220 - PubMed
  77. Acta Neuropathol. 2016 Jun;131(6):803-20 - PubMed
  78. Mol Endocrinol. 2002 Jan;16(1):100-15 - PubMed
  79. Am J Pathol. 2017 May;187(5):940-953 - PubMed
  80. PLoS One. 2017 Feb 24;12(2):e0172234 - PubMed
  81. Int J Cancer. 2012 Aug 1;131(3):601-11 - PubMed
  82. Cancer Res. 2010 Aug 15;70(16):6437-47 - PubMed
  83. Am J Clin Pathol. 2001 May;115(5):719-24 - PubMed
  84. Eur J Cancer Care (Engl). 2010 Jan 1;19(1):39-44 - PubMed
  85. Biochim Biophys Acta. 2009 Feb;1793(2):354-67 - PubMed

Publication Types